Serum biomarkers interleukin (IL)-6 and IL-1b were measured at each phase.<h4>Results</h4>Patients with HL demonstrated significant reduction in aortic TBR after first-line treatment (median GLA-TBR baseline: 1.98, median GLA-TBR third scan: 1.75, median difference = -0.20, 95% CI: -0.07 to -0.33, <i>P</i> = 0.006), which remained significant after adjustment for confounders (adj. The gene discussed is IL1B; the disease is Hodgkins lymphoma.